Related Experiment Video
Updated: Jan 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Pylephlebitis treated with apixaban
Graham R Hale1, Leon Alan Sakkal2, Taki Galanis3
1Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Abstract:
Pylephlebitis is a rare condition that is characterized by an infected thrombus of the portal vein system and was traditionally associated with a high mortality rate prior to the introduction of antibiotics. This report details a 77-year-old Chinese male found to have a splenic vein thrombosis, Parvimonas micra bacteremia, and a polymicrobial splenic abscess. The patient was treated with abscess drainage and a 6 week course of intravenous antibiotics, and a direct oral anticoagulant, apixaban 2.5 mg twice daily. To our knowledge, this is the second documented case of pylephlebitis treated with apixaban. Here, we summarize our experience treating this case of pylephlebitis and briefly report on the existing body of literature.
Insights
Pylephlebitis, a rare infected portal vein thrombus, was successfully treated in a 77-year-old male with splenic abscess and bacteremia. This case highlights the use of apixaban, a direct oral anticoagulant, in managing this serious condition.
Area of Science:
- Internal Medicine
- Infectious Diseases
- Vascular Surgery
Background:
- Pylephlebitis, an infected thrombus of the portal venous system, historically carries a high mortality rate.
- The advent of antibiotics significantly improved outcomes, but management remains challenging.
- Prompt diagnosis and multimodal treatment are crucial for patient survival.
Observation:
- A 77-year-old male presented with splenic vein thrombosis, Parvimonas micra bacteremia, and a polymicrobial splenic abscess.
- The patient underwent successful splenic abscess drainage.
- A six-week course of intravenous antibiotics was administered.
Findings:
- The patient received apixaban, a direct oral anticoagulant, at 2.5 mg twice daily for anticoagulation.
- This represents the second documented case of pylephlebitis treated with apixaban.
- The combination of abscess drainage, antibiotics, and anticoagulation led to a favorable outcome.
Implications:
- This case suggests that direct oral anticoagulants like apixaban may be a viable treatment option for pylephlebitis.
- Further research is warranted to establish the safety and efficacy of DOACs in managing pylephlebitis.
- Successful management underscores the importance of a multidisciplinary approach in treating complex infectious-thrombotic conditions.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Endocarditis IV: Nursing Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Pulmonary Embolism III: Nursing Management

